Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy

Código QR

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy

Guardado en:

Detalles Bibliográficos
Autores principales:	James Harber, Tamihiro Kamata, Catrin Pritchard, Dean Fennell
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ec617c8f1741449aae61038030de8918
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
por: Min Zhang, et al.
Publicado: (2021)

Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
por: Min Zhang, et al.
Publicado: (2021)

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
por: Yaolin Xu, et al.
Publicado: (2021)

A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment
por: A. Farias, et al.
Publicado: (2021)

Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy
por: Zhao P, et al.
Publicado: (2021)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Frank Riemer, et al.
Publicado: (2021)

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies
por: Wenwen Yang, et al.
Publicado: (2021)

CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
por: A. V. Bogolyubova, et al.
Publicado: (2015)

Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
por: Francesca Cersosimo, et al.
Publicado: (2021)

Metabolomic adaptations and correlates of survival to immune checkpoint blockade
por: Haoxin Li, et al.
Publicado: (2019)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: N. Jacquelot, et al.
Publicado: (2017)

Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
por: Dobrin Draganov, et al.
Publicado: (2021)

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer
por: Zhihao Lu, et al.
Publicado: (2021)

Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
por: Katrin Aslan, et al.
Publicado: (2020)

Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer
por: Jun Zhao, et al.
Publicado: (2019)

Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
por: Pei-Yi Chu, et al.
Publicado: (2021)

Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
por: Xiaopin Duan, et al.
Publicado: (2019)

Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade
por: Sebastian R. Nielsen, et al.
Publicado: (2021)

9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
por: Guangchun Han, et al.
Publicado: (2021)

Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
por: Yeon Jeong Kim, et al.
Publicado: (2021)

Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1
por: Marine Leclerc, et al.
Publicado: (2019)

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
por: Shohei Koyama, et al.
Publicado: (2016)

Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
por: Qian Chen, et al.
Publicado: (2016)

Development of a Flow Cytometry Assay to Predict Immune Checkpoint Blockade-Related Complications
por: Hannah-Lou Schilling, et al.
Publicado: (2021)

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
por: Johannes Griss, et al.
Publicado: (2019)

Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis
por: James A. Hutchinson, et al.
Publicado: (2021)

Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy
por: Antonella Cardinale, et al.
Publicado: (2021)

Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
por: Rei Hashimoto, et al.
Publicado: (2021)

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy
por: Yan‐Xing Chen, et al.
Publicado: (2021)

Tumor microenvironment: the formation of the immune profile
por: E. K. Oleinik, et al.
Publicado: (2020)

Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis
por: Chie Miyabe, et al.
Publicado: (2021)

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
por: Anna Morena D’Alise, et al.
Publicado: (2019)

The roles of exosomal immune checkpoint proteins in tumors
por: Cheng Xing, et al.
Publicado: (2021)

Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma
por: Alessandra Lopes, et al.
Publicado: (2018)

Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
por: Guru Sonpavde, et al.
Publicado: (2021)

Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade
por: Zia Khan, et al.
Publicado: (2021)

PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
por: Qi Peng, et al.
Publicado: (2020)

Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
por: Chisato Ohe, et al.
Publicado: (2021)

PD-1 immune checkpoint blockade may be viable for the prevention and treatment of elderly patients with POCD [Letter]
por: Wei P, et al.
Publicado: (2019)

The therapeutic implications of the genomic analysis of malignant pleural mesothelioma
por: Marjorie G. Zauderer
Publicado: (2021)